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transplantation (SCT) for lymphomas and the engraftment of 
donor immnnocompetent cells is essential. The height of host 
"immunological barrier" belongs to the major factors influencing 
engraftment. Some patients transplanted after non myeloablative 
regimens finally reconstituted their own immunocompetent cells 
because of insufficient immunosuppression and there has been no 
room for GvL effect. On the other hand, many pretrcated 
immunocompromised r cipients developed severe complications 
due to unnecessary toxicity. 11 patients with non-hodgkin lym 
pbomas (NHL - 8x) and chronic lymphatic leukemia (CLL - 3x) 
underwent non-myeloablative allogeneie SCT fronl sibling donor. 
No one of them was in complete remision (CR) before SCT. The 
recipients with the pretransplant level of CD3+ cells below than 0, 
5x10 9/L were grafted after conditioning combined flndarabin 
(125rag/m2) and cyclophosphamide (120mg/kg). Those ones with 
CD3+ cells above 0, 5x10 9/L underwent SCT after fludarabin 
and melphalan (140rag/m2), fludarabin, melphalan and ATG 
(40mg/kg)or fludarabin, cyclophosphamide and ATG. The "graft 
versus host disease" (GvHD) prophyla~s consisted of cyclosporine 
A (CsA) only or CsA combined with the short-course of 
methotrexate (MTX). Donor chilnerism was evaluated in T-cell 
population at day +30, +60, +100 after SCT. CsA tapering 
depended on the grade of donor chimerism in T-cells. 10 patients 
(90, 0%) achieved complete donor chimerism in T-cells and sus- 
tained CR of their disease at the posttransplant follow-up period 
(median 134 days). 6 recipient (54, 5%) developed GvHD. 3 
patients (27, 3%) died of transplant-related complications. The 
combination of fludarabin and cyclophosphamide (+/- ATG) was 
associated with significantly lower to ,  city and allowed sufficient 
engraftment of donor cells with effective immunological mmour 
control in severe immunocompromised hosts. The reduction of 
conditioningorelated o,city without he decrease of CR rate fully 
advocate the pretransplant evaluation of T-cell populations in 
recipients. 
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COMPARISON OF THREE CONDITIONING REGIMENS FOR AUTOLOGOUS 
STEM CELL TRANSPLANTATION IN NON-HODGKINS LYMPHOMA 
Fein, S.G.; O[,ersteim E., GoochnaJ1, M.; Byrnes, J.; Fe1"mmde~, H.F. 
Hemc/tolo~JO71cologv, Uniz,e'rsio~ of3/lkmli, ~ limni, FL. 
The optimal conditioning regimen for non-Hodgkins Lynx- 
phoma (NHL) patients receiving autologous helnatopoietic stem 
cell (HSC) transplantation remains uncertain. In many centers, 
cyclophosphamide and total body irradiation (FBI) have been 
replaced by combination chemotherapy regimens. One of these is 
busulfan(BU) and oyclophosphamide(CY). Recent studies suggest 
that intravenous busulfan may be more efficacious than oral busul- 
fan, partly attributable to more predictable pharmacokineties. To 
compare these conditioning regimens, we reviewed 63 autologous 
HSC transplants performed at our institution fi'om 1994-2002. 
Among these, 22 patients with NHL (73 % interinediate or high 
grade) were treated with cyclophosphamide 120 mg/kg and TBI 
1200 cGy given as divided daily fractions for 3 days (Cy/TBI), 18 
patients (78% intermediate grade) with oral busulfan 16 mg/kg 
and eyclophosphamide 120 mg/kg (Oral Bu/Cy), and 23 patients 
(91% intermediate grade) with intravenous busulfan I2.8 mg/kg 
with cyelophosphamide 120 mg/kg (IV Bu/Cy). The median age 
for each of the three groups was comparable. The groups differed 
with respect o number of pre-transplant chemotherapy treat- 
ments- 36% of Cy/TBI heavily pre-treated (more than 8 cycles of 
chemotherapy), compared to 64% of oral Bu/Cy and 77% of IV 
Bu/Cy. The IV Bu/Cy patients were more likely to be pre-treated 
with rituximab (45%) than Cy/TBI (0%) and oral Bu/Cy (6%). 
Treatment-related toxicity and mortality were comparable, 
though both busulfan cohorts had a longer time to engraftment. 
Median follow-up times were 7.1 years (Cy/TBI), 3.6 years (oral 
Bu/Cy), and 2.1 years (IV Bu/Cy). Overall (OS) and relapse-free 
survivals (RFS) at two years were 77% and 59% (Cy/TBI), 61% 
and 56% (oral Bu/Cy), and 71% and 71% (IV Bu/Cy). Although 
follow-up is short, Kaplan-Meier survival analysis suggests a trend 
towards improved RFS among IV Bu/Cy patients. Log-rank com- 
parison of the OS curves reveals no significant,difference amongst 
the three groups. Based on this review, the to,city and efficacy 
are comparable using IV Bu/Cy, Cy/TBI or oral Bu/Cy, as the 
conditioning regimen in autologous HSC transplant for NHL. 
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AUTOLOGOUS HENATOPOIETIC STEM CELL TRANSPLANTATION FOR 
TREATMENT OF MULTICENTRIC CASTLEMAN'S DISEASE/POEMS 
SYNDROME 
ChaTnm'thy, U.; ffmmkirnma'a, N.; tGnnboj, G.; AbdeLRnheem, M.; 
Rl~y, ti2; Pnrikh, D. Hem / 07zc / BMT, Hem 7 FoJ'd He~dth @stem, 
Detroit, 1~iI. 
BACKGROUND: POEMS (polyneuropathy, organomegaly, 
endocrinopathy, M proteiu, skin changes) syndrome, a rare nmlti- 
systemic disorder, is associated with nmlticentric Castleman's dis- 
ease (MCD) in 50% of cases. The treatment of MCD remains a 
challenge. There have been reports of limited and variable effective- 
ness using steroids, chemotherapy and imlnnnomodnlators (anti- 
IL6, interferon, Rituximab). There has only been one previous case 
report (Repetto et al. 1986) using" HDCT/HSCT. We report a case 
of MCD/POEMS successfully treated with high dose chemothera- 
py (HDCT) and hematopoietic stem cell transplantation (HSCT). 
CASE RESENTATION: A previously healthy 24 year-old male 
presented witb a rapidly progressing (demyelinating/axonal) eu- 
ropathy, initially involving the lower, and eventually the upper 
extremities - around November 2000. Within three months the 
patient became wheel-chair bound (ECOG Performance status=4), 
developed generalized lymphadenopathy, hepato splenomegaly and 
gynecomastia. Lymph node and bone marrow biopsies were non- 
diagnostic. He undei~vent splenectomy in May, 2001. The patholo- 
gy showed angiofollicnlar hyperplasia consistent with Castleman's 
disease. He had low testosterone levels, Ig A ~ monoclonal protein 
in the serum, and cutaneous helnangiomas. Serologic screening for 
HIV and IIHV-8 were negative. With these findings, a diagnosis of 
MCD/POEMS was established. Therapeutic trials of steroids, Rit- 
nximab, IVIG, Cyelophosphamide/prednisone failed. Given his 
young age and rapid clinical deterioration he was offered high dose 
chemotherapy with HSCT. Peripheral blood stem cells were har- 
vested using Cyclophosphamide (3g/mZ)/G-CSF (10~tg/Kg). The 
patient was given Melphalan (200mg/m -~) as conditioning regimen, 
followed by antologons tem cell infusion. Hospital course was 
complicated by febrile neutropenia and choleeystitis. Clinical and 
radiological resolution of all lymphadenopathy occurred within 4 
weeks. He also had gradual recovery of his neurological deficits and 
hepatomegaly. The patient remains in remission a year later 
(ECOG PS=0) CONCLUSION High-dose chemotherapy with 
autologous hematopoietic stem cell transplant resulted in complete 
remission of aggressive and refractory MCD/POEMS syndrome 
with a durable response at one year. HDCT/HSCT is a novel treat 
ment option for this rare but challenging disease. 
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CD34+ COUNTS AFTER ETOPOSIDE AND CYCLOPHOSPHAMIDE PLUS 
G-CSF MOBILIZATION VERSUS G-CSF ALONE IN MULTIPLE MYELOMA 
PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION 
Pie'rce, T.N[; Scott, L.M.; White, M.; Agv~'_n, E.; Bero,mlm, R.B.; Ftlv, 
J. t,f,~; ~mzce, E.; Ph~eiro, L. . 
There were 83 patients who had an autologous transplant for 
multiple myeloma. All patients had a myeloablative r gimen with 
26 (31%) receiving" Melphalan, 55 (66%) received 
Melphalan/Total Body Irradiation (TBI). There was 1 patient 
who received ThioTepa/TBI and 1 who received Cyclophos- 
phamide/TBI as the conditioning regimen. Of the 83 pts, there 
were 58 (70%) who received mobilization with a continuous infu- 
sion of etoposide (2400mg/m2 over 34 hours) followed by 
cyclophosphamide 150 mg/kg followed by G-CSF at a dose of 5 
mcg/kg/day. There were 25 patients (30%) that received mobi 
lization with G-CSF only at a dose of 16 mcg/kg/day. For the 
patients who received chemotherapy mobilization, the average 
nmnber of PBSC collections required was 1.8 (Range 1 to 7, 
median=l). Of the patients who received G-CSF mobilization, the 
average number of collections was 2.8 (Range 1 to 5, median=2). 
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The average CD34+ collection was 31.9 X 106/kg with the 
chemotherapy mobilization group and 6.7 X 106/kg with the G- 
CSF alone group. The target ceil dose was 2.0 X 106/kg. 
Chemotherapy with etoposide and cyclophosphamide is an effec- 
tive means for mobilization of large numbers of CD34+ cells. This 
may offer an advantage over G-CSF mobilization alone in multi- 
ple myeloma patients who may benefit from receiving additional 
cytoreductive therapy. 
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NON-MYELOABLATIVE ALLOGENEIC PERIPHERAL STEM CELL TRANS- 
PLANTATION IN MULTIPLE MYELOMA: 2 YEARS EXPERIENCE IN A 
SINGLE CENTER 
Lie, K.; Limlg, R.; Kwong, Y.; Chim, C.; Au, W.; Ma, S. Queen 3da'J 7 
Hosptial, Ho77g Ko~zg, HoJzg Kong. 
Multiple myeloma (MM) is considered incurable by 
chemotherapy alone and the role of standard allogeneic stem 
cell transplantation (allo-SCT) remains limited because of rela- 
tively high treatment-related mortality (TRM). Non-myeloab 
lative allo-SCT is associated with satisfactory engraftment but 
less toxicity, which is essential in the heavily pretreated elderly 
patient with MM. We report our 2 years experience on 10 MM 
patients receiving non-myeloablative allogeneic PBSC trans- 
plantation using fludarabine 30 rag/m2 daily for 3 days plus 
total body irradiation 1.5 Gy daily for 2 days as conditioning. 
All patients received repeated courses of chemotherapy for 
active disease before SCT. Eight patients had full HLA- 
matched siblings donor, 1 had a one major HLA-antigen ntis- 
matched sibling and 1 had a HLA matched daughter donor. 
All 10 patients had satisfactory engraftment before D21. No 
TRM was observed uring the whole follow up period. Acute 
GVHD developed in 3 patients (2 at grade III and 1 at grade 
IV) and 7 patients had chronic GVHD (3 acute GVHD cases 
included). At a median follow up of 1 year, 2 patients had com- 
plete remission (CR), 3 patients had partial response (PR), 3 
patients had no response (NR) and 2 patients were too early 
for assessment. No relapse was observed in the 2 patients with 
CR. Only one NR patients had donor lymphocyte inf\lsion 
(DLI) and 2 NR patients had thalidomide. In conclusion, non- 
myeloablative allo-SCT in multiple myeloma is effective with 
less toxicity and TRM. However, a longer follow up period 
and more cases are required before a definite conclusion can be 
reached. 
PEDIATRIC DISORDERS 
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ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHILDREN 
WITH MYELOID HEMATOLOGIC MALIGNANCIES 
Hale, G.A.; Czlmdngham, ff.M.; Heslop, H.E.; Krame, R.A.; Richard- 
sot*, S.; To~g, X.; Be~mim, E.; Ho~witz, E.M.; Lemzg, ~t':; Srivastava, 
D.K.; Woodard, ff.P.; Bowman, L.C.; Handgretinger, R. Hematol- 
ogy/Omology, St. Jude Children's Research Hospital, Memphis, TN. 
Allogeneic BMT is curative for certain patients with AML, 
CML, or myelodysplasia (MDS). We r~viewed the records of 317 
patients who underwent allogeneic BMT at St. Jude Children's 
Research Hospital between 1992-2000 and identified 183 with 
myeloid malignancies. Diagnoses included de novo AML (n=76), 
de novo MDS (n=39), secondary AML/MDS (n=23), JCML (n=3), 
CML (n=40), or other myeloid disease (n=2). The median age at 
BMT was 11.2 years; 19 had undergone a prior autograft. 63 pts. 
received grafts from matched sibling donors (MSD), 98 from 
unrelated onors (MUD), and 22 from mismatched family mem- 
ber (MMFM) donors. All pts. received cyclophosphamide, cytara- 
bine, and TBI. ATG was given to 90 pts. who received marrow 
from MUD or MMFM donors to enhance immunosuppression. 
MUD and MMFM marrow was depleted of T-lymphocytes using 
monoclonal antibodies against CD6 and CD8 with rabbit comple- 
ment; MSD grafts were unmanipulated. Cyclosporine was given 
to all pts.; pentoxiphylline or short-course methotrexate w re pro- 
vided to recipients of MSD grafts. Variables analyzed included 
patient gender, patient age, diagnosis, prior autograft, second 
malignancy, disease status at BMT, donor-recipient ABO match, 
donor-recipient gender, donor-recipient CMV serology, patient 
CMV serology, use of ATG, HLA class i match, HLA class II 
match, donor type and degree of match, and the use of T-cell 
depletion. The cumulative incidence of engraftment was 96.7% 
with median of 19 days to ANC >500/ram3. Grade II IV acute 
GvHD occurred in 22%; chronic GvHD occurred in 16%. The 5- 
year probabilities of overall (OS)and disease-free survival (DFS) 
were 48% and 44%, respectively. At 5 years, the culnulative inci- 
dence of non-relapse mortality was 34% for AML, 20% for MDS, 
and 27% for CML. T i le cumulative incidence of relapse was 28% 
for AML, 24% for MDS, and 5% for CML. Favorable prognostic 
factors for OS were a CML diagnosis, not having a second malig- 
nancy, donor-recipient HLA Class I match, lower T cell graft 
content, and donor-recipient donor match (MSD and MUD) by 
nnivariate analysis. Multiple regression analysis revealed that T- 
cell dose, diagnosis, second malignancy, and HLA Class I match 
were significant factors for OS. This large pediatric study 
describes outcomes, complications and prognostic factors for sur- 
vivial in children undergoing BMT for myeloid iseases. 
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FAVORABLE RESULTS OF UNRELATED UMBILICAL CORD BLOOD 
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CHRONIC MYEL- 
OGENOUS LEUKEMIA 
Km~tzl, erg, J.; Szabolcs, P.; DrLrcoll, 72; 3/hlstr~, M.; Wood, S.; Shon- 
kwilev, A.; 3/lart&, P.L. Pediatrics, Dl~ke University Medical Center; 
Dut'ham, NC. 
Philadelphia + chronic myelogenous leukemia (CML) is a rare 
form of leukemia in children which is cured by allogeneic stem 
cell transplantation (SCT). Many pts cannot identi~ a donor. 
Over the past 7 years, we transplanted 11 pediatric pts, lacking 
matched living stem cell donors, with unrelated umbilical cord 
blood (UCB). The study group was comprised of 7 males and 6 
(55%) pts who were ethnic minorities with a median age of 13.25 
years (range 1.9-17.4) and median weight of 40.4 kg (range 13.3- 
58.8). Four pts were in first chronic phase (CP), 2 in 2nd CP, 2 in 
accelerating phase, and 3 in blast crisis (BC). The preparative r gi- 
men was TBI/Melphalan/ATG in 7 pts, TBI/Cytoxan/ATG in 2 
pts, Fludarabine/Melphalan/ATG in 1 pt and Busulfan/Melpha- 
lan/ATG in 1 pt. Cyclosporine and solumedrol were used for 
GvHD prophylaxis. Grafts were matched at HLA Class I, A and B 
at the serologic level and HLA Class II, DRB1 at allelic level. 
YVith this matching strategy, they matched at 6/6 HLA loci in I 
pt, 516 in 5 pts, 4/6 in 4 pts, and 3/6 in l pt. The grafts delivered a
median of 3.09 x 10e7 (range 0.96-9.07) nucleated cells/kg pre- 
cwopreservation. The median CD34 dose delivered post thaw was 
0.89 x 10e5/kg (range 0.16-1.54). Ten of 11 pts (91%) engrafted 
with donor cells. The non-engrafting pt remained in BC and 
received a 3/6 graft. Of engrafting pts, the median time to neu- 
trophil recovery" (ANC>5OO/uL) was 24 days (range 12-37) and 
platelet recovery (platelets >50K untransfused) was 71 days (range 
27-112). Three patients developed severe grade III GvHD and 1 
pt developed extensive chronic GvHD. Four patients died, 1 of 
recurren~ pulmonary alveolar hemorrhage, 2 of infection with 
GvHD, and 1 of CML. The remaining 7 pts (64%) are surviving 
in remission from 2-38 months (median 24 ) post transplant. As 
exp, ected, 83% of patients transplanted in first or second CP are 
doing well, while only 1/3 transplanted in BC is a long term sur- 
vivor. These results are superior to those from initial cord blood 
registries which predominantly reflected results in adult patients 
with advanced isease. We conclude that unrelated UCB donors 
should be actively considered for pediatric pts with CML lacking a 
living related or unrelated stem cell donor to enable transplanta- 
tion in the first chronic phase of the disease. 
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